Qube Research & Technologies (QRT)
ACRV icon

Qube Research & Technologies (QRT)’s Acrivon Therapeutics ACRV Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,692
Closed -$15.1K – 3531
2025
Q2 		$15.1K Buy
+12,692
New +$17.4K ﹤0.01% 3283
2024
Q1 		– Sell
-260
Closed -$1.28K – 4407
2023
Q4 		$1.28K Buy
260
+122
+88% +$644 ﹤0.01% 3851
2023
Q3 		$1.32K Buy
+138
New +$1.59K ﹤0.01% 3612

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ACRV Position: Q3 2025 in Review

Qube Research & Technologies (QRT) sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 12,692 shares — an estimated $15.1K sold.

Qube Research & Technologies (QRT) first reported a position in ACRV in Q3 2023 and held it in 3 quarters. The position peaked at $15.1K in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

  • Qube Research & Technologies (QRT) reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 12,692 Acrivon Therapeutics shares in Q3 2025, an estimated $15.1K.
  • Qube Research & Technologies (QRT) first reported a position in Acrivon Therapeutics in Q3 2023 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s Acrivon Therapeutics position peaked at $15.1K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2025, filed 14 Nov 2025.